Novel Therapeutic Approaches to Inhibit Type 2 Inflammation

Johnson & Johnson Innovation is seeking novel therapeutic approaches to inhibit type 2 inflammation. Approaches which have a systemic effect on type 2 inflammation in relevant diseases (e.g., atopic dermatitis, asthma, eosinophilic esophagitis) are of interest. 

Novel oral therapeutic strategies targeting the Th2 signalling pathway are of particular interest (e.g., small molecule inhibitors of STAT6, IL-4R etc.). Approaches targeting other relevant pathways are also of interest if they provide a systemic approach with transformational therapeutic potential in type 2 inflammatory conditions.

Approaches of Interest:

• Small molecules, peptides, large molecules and multi-specifics

Developmental Stages of Interest:

• Opportunities from preclinical research to phase III stage are within scope
• Opportunities should have at least in vitro validation with supporting data. Opportunities with in vivo and later stage validation are of interest, provided they are novel therapeutic approaches 

Out of Scope:

• Approaches using inhaled or topical delivery
• Microbial therapies
• Drug repurposing
• Therapeutic approaches that do not have clear differentiation from current approved therapies

Submission Information

Submission of one page, 200-300 word briefs are encouraged, along with any optional supplementary information e.g. relevant publications. In submitting to this campaign, you confirm and acknowledge that your submission (i) contains only non-confidential information, (ii) creates no obligation of confidentiality (or any other obligation) on any recipient, and (iii) does not infringe or misappropriate any third-party rights. 

Opportunity for Collaboration

Johnson & Johnson Innovation is open to a range of potential collaboration opportunities, with the most appropriate outcome being decided in their sole discretion and on a case-by-case basis. Example outcomes may include licensing assets, project/PhD funding, and research collaborations.